References

All-Party Parliamentary Group on Primary Headache Disorders. Headache disorders—not respected, not resourced. 2010. https://www.migrainetrust.org/wp-content/uploads/2015/12/2010Mar-APPGPHD_REPORT_Headache_Disorders-NotRespNotReso.pdf (accessed 9 March 2020)

Drachman DB. Atrophy of skeletal muscles in chick embryo treated with Botilinum toxins. Science. 1964; 145:719-21 https://doi.org/10.1126/science.145.3633.719

Escher CM, Paracka L, Kollewe Dressler D Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord. 2016; 10:(2)127-135 https://doi.org/10.1177/1756285616677005

Jabbari B. History of Botulinum toxin treatment of movement disorders. Tremor other hyperkinet Mov (NY). 2016; 6 https://doi.org/10.7916/D81836S1

National Institute for Health and Care Excellence. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. 2012. https://tinyurl.com/s8fls8z (accessed 9 March 2020)

Rose FC. The history of migraine from Mesopotamian to Medieval times. Cephalalgia. 1995; 15:(S15)1-3 https://doi.org/10.1111/J.1468-2982.1995.TB00040.X

Scott A. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Opthamology. 1980; 87:1044-1049 https://doi.org/10.1016/s0161-6420(80)35127-0

Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as migraine preventive treatment. For the Botox and migraineclinical research group. Headache. 2000; 4:445-450 https://doi.org/10.1046/j.1526-4610.2000.00066.x

Steiner TJ The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003; 23:(7)519-527 https://doi.org/10.1046/j.1468-2982.2003.00568.x

Torrens J. Clostidium botulinum was named because of association with ‘sausage poisoning’. BMJ. 1998; 316 https://doi.org/10.1136/bmj.316.7125.151c

Waseem Z Botulinum toxin injections for low-back pain and sciatica. Cochrane Database Syst Rev. 2011; 1 https://doi.org/10.1002/14651858.CD008257.pub2

Wollmer MA, de Boer C, Kalak NT Facing depression with Botulinum toxin: a randomized controlled trial. J Psychiatr Res. 2012; 46:574-581 https://doi.org/10.1016/j.jpsychires.2012.01.027

Psychology
Injectables

Botulinum toxins in the treatment of migraines

02 April 2020
Comment
02 April 2020
Volume 9 · Issue 3

Abstract

Ten years ago, Botulinum toxin was approved by the US Food and Drug Administration for the treatment of migraines. Dr Tariq Sumrein details how this effective treatment works and what this means for aesthetic practitioners and the future of aesthetic medicine

In 2010, the US Food and Drug Administration (FDA) approved the use of botulinum toxins (BoTN) in the treatment of migraines and, one year later, the National Institute for Health and Care Excellence (NICE) approved it for the use in UK (NICE, 2012; Escher et al, 2016).

All the medical evidence proved that it is an effective way of treating this widely spread disease, which is rated as the seventh cause of medical disability worldwide.

Currently, the treatment is provided by some of the migraine clinics in the NHS, private GPs, neurologists and aesthetic practitioners.

The word ‘migraine’ derives from the Greek word ‘hemicrania’ (imikrania; ημικρ ανία), which means ‘half the skull’, as, typically, most patients have unilateral headaches. With the new diagnosis criteria, migraine could be all over the head, lasting for few hours or days (Rose, 1995).

Register now to continue reading

Thank you for visiting Journal of Aesthetic Nurses and reading some of our peer-reviewed resources for aesthetic nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month

Register
Or continue by

Signing in with your registered email address